^
Association details:
| Biomarker: | TP53 mutation + Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/03/2022
Excerpt:
SUGGESTED TREATMENT REGIMENS...CLL/SLL with del(17p)/TP53 mutation...Preferred regimens...Zanubrutinib
Source:
Title:
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Published date:
12/16/2021
Excerpt:
The ORR in patients with del(17p)/tumour protein p53 mutation was 87·5% (CR 16·7%). The 2- and 3-year progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) respectively…With a median follow-up of ~4 years, responses remain clinically meaningful and durable and long-term tolerability to zanubrutinib therapy continues.
DOI:
10.1111/bjh.17994
Source:
Title:
ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: 34-MONTH FOLLOW-UP RESULTS
Published date:
05/12/2021
Excerpt:
...patients with R/R CLL/SLL received oral zanubrutinib...Patients with del(17p) and/or TP53 mutation and del(11q) achieved high response rates of 91% (95% CI, 70.8%>98.9%) and 100% (95% CI, 83.2%>100%), respectively….Deep and durable responses were achieved in all patient subgroups including patients with high-risk cytogenetics. Data support the tolerability of long-term zanubrutinib treatment in R/R CLL/SLL, with no new safety signals identified.
